Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Repare Therapeutics ( (RPTX) ) has issued an announcement.
Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences under which Gilead will acquire all assets primarily related to Repare’s RP-3467 program, a clinical-stage treatment candidate for advanced solid tumors, while excluding Repare’s other pipeline programs, employee contracts, cash, receivables, and physical assets. The deal, approved by Repare’s board, provides for up to $30 million in cash consideration to Repare, including a $22 million payment by year-end 2025, up to $3 million in holdback subject to conditions after one year, and a $5 million payment upon successful completion of the asset transfer, potentially strengthening Repare’s balance sheet and allowing it to focus resources on its remaining oncology programs while Gilead takes over development of RP-3467 and associated liabilities going forward.
The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
The score is primarily held back by weak financial performance (revenue volatility, ongoing losses, and negative operating/free cash flow), partially offset by a relatively stable balance sheet and positive corporate events that strengthen cash. Technicals are constructive with an uptrend, but overbought signals temper the outlook, while valuation remains unfavorable due to losses and no dividend support.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics Inc. is a Québec-based clinical-stage biopharmaceutical company whose shares trade on Nasdaq under the symbol RPTX. The company focuses on developing targeted oncology therapies, including programs such as RP-1664 and lunresertib/camonsertib, aimed at treating advanced solid tumors.
Average Trading Volume: 882,977
Technical Sentiment Signal: Hold
Current Market Cap: $110.8M
See more insights into RPTX stock on TipRanks’ Stock Analysis page.